All news

H.C. Wainwright keeps Buy, USD 8.00 Prelude target

Alpha Vantage · ad-hoc-news.de · · AI-summarised by FinFlash

H.C. Wainwright reiterated its Buy rating and USD 8.00 price target on Prelude Therapeutics after the company struck a collaboration with Eli Lilly for a Phase 1 breast cancer trial. The deal gives Prelude access to Lilly's drugs for combination cohorts testing PRT13722, an oral KAT6A selective degrader, with patient enrollment expected in Q4 2026.

Read original source

PRLD company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.